Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies-Reference-Cited by-同舟云学术

Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies

Published:2019-11 Issue: Volume:36 Page:101335
ISSN:2211-0348
Container-title:Multiple Sclerosis and Related Disorders
language:en
Short-container-title:Multiple Sclerosis and Related Disorders

Author:

Haas Judith,Jeffery Douglas,Silva Diego,Meier Daniela Piani,Meinert Rolf,Cohen Jeffrey^ORCID,Hartung Hans-Peter

Publisher

Elsevier BV

Subject

Neurology (clinical),Neurology,General Medicine

Reference45 articles.

1. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis;Bergvall;Curr. Med. Res. Opin.,2014

2. Relapse rates in patients with multiple sclerosis switching from interferon to fingolimod or glatiramer acetate: a US claims database study;Bergvall;PLoS One,2014

3. Predictors of long-term outcome in multiple sclerosis patients treated with interferon beta;Bermel;Ann. Neurol.,2013

4. Therapeutic management of severe relapses in multiple sclerosis;Bevan;Curr. Treat. Options Neurol.,2015

5. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial;Calabresi;Lancet Neurol.,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Autologous Stem Cell Transplantation for Autoimmune Diseases;Comprehensive Hematology and Stem Cell Research;2024

2. Drug repurposing for neurodegenerative diseases;Progress in Molecular Biology and Translational Science;2024

3. Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical setting;Multiple Sclerosis and Related Disorders;2023-09

4. The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis;Drugs in R&D;2023-08-28

5. Assessment of Functional Capacity of Immune System in Patients with Multiple Sclerosis using QuantiFERON Monitor;Journal of Immunology Research;2023-04-07